Drug intelligence / Profile preview

all-trans retinoic acid + rituximab

Development stage: Unknown
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

A combination of all-trans retinoic acid (ATRA), a retinoid that promotes cell differentiation, and rituximab, a CD20-directed monoclonal antibody. ATRA works by binding to retinoic acid receptors (RAR) and retinoid X receptors (RXR), causing immature blood cells to develop into normal blood cells. Rituximab targets the CD20 antigen found on the surface of B cells, leading to B-cell depletion through various mechanisms including antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.

Other names: ATRA + rituximabtretinoin + rituximab

Targets

CD20 (B-lymphocyte antigen CD20)RAR (Retinoic acid receptor)

Beyond the preview

Go deeper on all-trans retinoic acid + rituximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on all-trans retinoic acid + rituximab.

Explore the full profile